惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Y
Y Combinator Blog
S
SegmentFault 最新的问题
WordPress大学
WordPress大学
让小产品的独立变现更简单 - ezindie.com
让小产品的独立变现更简单 - ezindie.com
美团技术团队
博客园 - 叶小钗
大猫的无限游戏
大猫的无限游戏
罗磊的独立博客
Hugging Face - Blog
Hugging Face - Blog
博客园 - 司徒正美
小众软件
小众软件
博客园 - 聂微东
阮一峰的网络日志
阮一峰的网络日志
博客园 - 三生石上(FineUI控件)
月光博客
月光博客
The Cloudflare Blog
T
Tailwind CSS Blog
博客园 - 【当耐特】
Jina AI
Jina AI
量子位
有赞技术团队
有赞技术团队
博客园 - Franky
V
Visual Studio Blog
V
V2EX

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript
2026-05-08 · via All Articles on Seeking Alpha

Natera, Inc. (NTRA) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDT

Company Participants

Mike Brophy - Chief Financial Officer
Steve Chapman - CEO & Director
Solomon Moshkevich - President of Clinical Diagnostics
Alexey Aleshin - GM of Oncology and Early Cancer Detection & Chief Medical Officer

Conference Call Participants

Douglas Schenkel - Wolfe Research, LLC
Daniel Brennan - TD Cowen, Research Division
Patrick Donnelly - Citigroup Inc., Research Division
Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division
Kallum Titchmarsh - Morgan Stanley, Research Division
Casey Woodring - JPMorgan Chase & Co, Research Division
Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division
Puneet Souda - Leerink Partners LLC, Research Division

Presentation

Operator

Ladies and gentlemen, welcome to Natera's First Quarter 2026 Financial Results Conference Call.

[Operator Instructions]

As a reminder, this conference call is being recorded today, May 7, 2026. I would now like to turn the conference over to Michael Brophy, Chief Financial Officer. Please go ahead.

Mike Brophy
Chief Financial Officer

Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss the results of our first quarter of 2026. On the line, I am joined by Steve Chapman, our CEO; Solomon Moshkevich, President, Clinical Diagnostics; Alex Aleshin, General Manager of Oncology and our Chief Medical Officer.

Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be posted to our IR website as soon as it's available.

Starting on Slide 2. During the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance such as our operational and financial outlook and projections, our assumptions for that outlook, market size, partnerships, clinical studies and expected results, opportunities and strategies and expectations for current and future products, including product capabilities, expected release